<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02133339</url>
  </required_header>
  <id_info>
    <org_study_id>TRN-157-101</org_study_id>
    <nct_id>NCT02133339</nct_id>
  </id_info>
  <brief_title>Single Ascending Dose Study of TRN-157 in Healthy Subjects</brief_title>
  <official_title>A Phase I, Randomized, Double-blind, Placebo Controlled, Single Ascending Dose Study to Evaluate the Safety and Tolerability of Nebulized, TRN-157 Inhalation Solution in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Theron Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Theron Pharmaceuticals, Inc.</source>
  <brief_summary>
    <textblock>
      This single ascending dose study is to determine and evaluate the safety and tolerability of&#xD;
      TRN-157 in approximately 40 healthy subjects.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Actual">September 2014</completion_date>
  <primary_completion_date type="Actual">August 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability as determined by number of subjects with adverse events</measure>
    <time_frame>1 week</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determination of pharmacokinetic parameters</measure>
    <time_frame>1 week</time_frame>
    <description>Area Under the Plasma Concentration-Time Curve from Zero to the Time of the Last Measurable Concentration (AUC0-t)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determination of pharmacokinetic parameters</measure>
    <time_frame>1 week</time_frame>
    <description>Area Under the Plasma Concentration-Time Curve from Zero to Infinity (AUC0-inf)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determination of pharmacokinetic parameters</measure>
    <time_frame>1 week</time_frame>
    <description>Peak Plasma Concentration (Cmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determination of pharmacokinetic parameters</measure>
    <time_frame>1 week</time_frame>
    <description>Time to Peak Plasma Concentration (tmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determination of pharmacokinetic parameters</measure>
    <time_frame>1 week</time_frame>
    <description>Half-Life (t½)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determination of pharmacokinetic parameters</measure>
    <time_frame>1 week</time_frame>
    <description>Elimination Rate Constant (kel)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determination of pharmacokinetic parameters</measure>
    <time_frame>1 week</time_frame>
    <description>Volume of Distribution at Steady State after Non-IV Administration (Vss/F)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determination of pharmacokinetic parameters</measure>
    <time_frame>1 week</time_frame>
    <description>Total Plasma Clearance after Non-IV Administration (CL/F)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <arm_group>
    <arm_group_label>TRN-157</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TRN-157</intervention_name>
    <arm_group_label>TRN-157</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subject has provided written informed consent&#xD;
&#xD;
          2. The subject is male or female 18 to 65 years of age&#xD;
&#xD;
          3. If the subject or subject's partner is of childbearing potential, a medically&#xD;
             acceptable form of contraception will be&#xD;
&#xD;
          4. Non-smoker&#xD;
&#xD;
          5. Good general health&#xD;
&#xD;
          6. Willing to abstain from alcohol, caffeine, and xanthine-containing beverages&#xD;
&#xD;
          7. The subject is compliant and available throughout the entire study period&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Current diagnosis, as per subject or investigator or screening assessment, of:&#xD;
&#xD;
               1. unstable or uncontrolled disease in any organ system (including cardiovascular)&#xD;
                  on present therapy&#xD;
&#xD;
               2. history of narrow angle glaucoma&#xD;
&#xD;
               3. history of alcohol abuse within the past 5 years&#xD;
&#xD;
               4. history of smoking within the past 6 months&#xD;
&#xD;
               5. positive result for the alcohol and/or drugs of abuse&#xD;
&#xD;
               6. weight &gt; 100 kg or &lt; 50 kg&#xD;
&#xD;
               7. clinically significant abnormal ECG&#xD;
&#xD;
               8. history of clinically significant (per the Investigator) disease or disorder&#xD;
&#xD;
               9. any clinically significant abnormalities in clinical chemistry, hematology, or&#xD;
                  urinalysis results&#xD;
&#xD;
              10. Abnormal vital signs defined as any of the following:&#xD;
&#xD;
                    -  Systolic blood pressure ≥ 140 mmHg&#xD;
&#xD;
                    -  Diastolic blood pressure ≥ 90mmHg&#xD;
&#xD;
          2. Heart rate &lt; 40 or &gt; 85 beats per minute&#xD;
&#xD;
          3. Fever or other clinically significant physical exam findings&#xD;
&#xD;
          4. Current or history of clinically significant respiratory disease, including asthma,&#xD;
             emphysema, chronic bronchitis, or cystic fibrosis&#xD;
&#xD;
          5. History or current symptom(s) of respiratory tract inflammation&#xD;
&#xD;
          6. Inability to perform reproducible spirometry in accordance with American Thoracic&#xD;
             Society (ATS) guidelines&#xD;
&#xD;
          7. Abnormal FEV1, FVC, or FEV1/FVC (FEV1 or FVC &lt; 80% of predicted or FEV1/FVC ratio &lt;&#xD;
             0.7)&#xD;
&#xD;
          8. FEV1 variability &gt; 10% between study visits&#xD;
&#xD;
          9. Female of childbearing potential with a positive serum pregnancy test or currently&#xD;
             breastfeeding&#xD;
&#xD;
         10. Currently being treated for hypertension or taking any other medications that affect&#xD;
             blood pressure significantly&#xD;
&#xD;
         11. Inability to perform acceptable, quality serial spirometry or any other study&#xD;
             procedures&#xD;
&#xD;
         12. Positive screen for Hepatitis B surface antigen (HBsAg), Hepatitis C antibody, or HIV&#xD;
             antibody&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joe Oren</last_name>
    <role>Study Director</role>
    <affiliation>Theron Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Cypress</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2014</verification_date>
  <study_first_submitted>May 5, 2014</study_first_submitted>
  <study_first_submitted_qc>May 7, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 8, 2014</study_first_posted>
  <last_update_submitted>October 29, 2014</last_update_submitted>
  <last_update_submitted_qc>October 29, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 31, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

